CStone Starts Phase III Trial of PD-L1 Candidate in Gastric Cancer Patients

CStone Pharma of Shanghai has started a China Phase III of its anti-PD-L1 antibody (CS1001) as a first-line treatment for gastric cancer. The specific indications for the trial are gastric adenocarcinoma (GC) or gastro-esophageal junction (GEJ) adenocarcinoma, which comprise over 90% of all gastric cancer cases. The multi-center, placebo-controlled trial will evaluate the efficacy and safety of CS1001 plus XELOX chemotherapy in patients with unresectable, locally advanced, or metastatic GC or GEJ adenocarcinoma. More details.... Stock Symbol: (HK: 2616) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.